Intensity's clinical data demonstrates abscopal effects (shrinkage of uninjected tumors) and increased immune activation, suggesting systemic immune engagement following local tumor destruction. The company has successfully extended cash runway and is executing pivotal late-stage trials, positioning itself for potential regulatory milestones in 2026-2027.
Cyborg Score Rationale
The company received a 180-day Nasdaq extension to regain compliance with the minimum $1.00 bid price requirement, reflecting liquidity pressures. However, analyst price targets average $56.25 with "Strong Buy" ratings, suggesting 690% upside potential, and clinical data showing immune activation provides mechanistic support for ongoing trials.
Top Insights
Q1 2026 protocol amendment planned to revise INT230-6 dosing in the INVINCIBLE-4 breast cancer trial
Cash runway extends into Q2 2027, indicating near-term funding requirement
Pathological complete response observed in early INVINCIBLE-4 Cohort A patients receiving two INT230-6 doses